These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 15679759)

  • 1. The effect of acid suppression on sleep patterns and sleep-related gastro-oesophageal reflux.
    Orr WC; Goodrich S; Robert J
    Aliment Pharmacol Ther; 2005 Jan; 21(2):103-8. PubMed ID: 15679759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of gastro-oesophageal reflux disease with rabeprazole in primary and secondary care: does Helicobacter pylori infection affect proton pump inhibitor effectiveness?
    Wit NJ; Boer WA; Geldof H; Hazelhoff B; Bergmans P; Tytgat GN; Smout AJ
    Aliment Pharmacol Ther; 2004 Aug; 20(4):451-8. PubMed ID: 15298640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20 mg vs. placebo: results of a 5-year study in the United States.
    Caos A; Breiter J; Perdomo C; Barth J
    Aliment Pharmacol Ther; 2005 Aug; 22(3):193-202. PubMed ID: 16091056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of a therapeutic trial of high-dose rabeprazole on symptom response of patients with non-cardiac chest pain: a randomized, double-blind, placebo-controlled, crossover trial.
    Dickman R; Emmons S; Cui H; Sewell J; Hernández D; Esquivel RF; Fass R
    Aliment Pharmacol Ther; 2005 Sep; 22(6):547-55. PubMed ID: 16167971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Frequency analyses of gastric pH in control and gastro-oesophageal reflux disease subjects treated with a proton-pump inhibitor.
    Gardner JD; Sloan S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1381-6. PubMed ID: 15606401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rabeprazole is equivalent to omeprazole in the treatment of erosive gastro-oesophageal reflux disease. A randomised, double-blind, comparative study of rabeprazole and omeprazole 20 mg in acute treatment of reflux oesophagitis, followed by a maintenance open-label, low-dose therapy with rabeprazole.
    Pace F; Annese V; Prada A; Zambelli A; Casalini S; Nardini P; Bianchi Porro G;
    Dig Liver Dis; 2005 Oct; 37(10):741-50. PubMed ID: 16024305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rabeprazole on early symptom relief in gastro-oesophageal reflux disease: the Hellenic Rabeprazole Study Group surveillance study.
    Archimandritis AJ; Nikolopoulou V; Kouklakis G; Paraskevas E; Avgerinos A; Tsianos E; Triantafillidis JK;
    Curr Med Res Opin; 2005 Apr; 21(4):603-10. PubMed ID: 15899110
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Review article: pH, healing and symptom relief with rabeprazole treatment in acid-related disorders.
    Robinson M
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():30-7. PubMed ID: 15496216
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Heartburn severity can predict pathologic oesophageal reflux in gastro-oesophageal reflux disease patients treated with a proton-pump inhibitor.
    Gardner JD; Sloan S; Robinson M; Miner PB
    Aliment Pharmacol Ther; 2003 Jul; 18(1):133-40. PubMed ID: 12848635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Onset of symptom relief with rabeprazole: a community-based, open-label assessment of patients with erosive oesophagitis.
    Robinson M; Fitzgerald S; Hegedus R; Murthy A; Jokubaitis L;
    Aliment Pharmacol Ther; 2002 Mar; 16(3):445-54. PubMed ID: 11876697
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of proton pump inhibitor utilization patterns on gastroesophageal reflux disease-related costs.
    Hall J; Dodd S; Durkin M; Sloan S
    Manag Care; 2002 Jul; 11(7 Suppl):14-8. PubMed ID: 12181872
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rabeprazole versus ranitidine for the treatment of erosive gastroesophageal reflux disease: a double-blind, randomized clinical trial. Raberprazole Study Group.
    Farley A; Wruble LD; Humphries TJ
    Am J Gastroenterol; 2000 Aug; 95(8):1894-9. PubMed ID: 10950032
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pantoprazole for sleepiness associated with acid reflux and obstructive sleep disordered breathing.
    Steward DL
    Laryngoscope; 2004 Sep; 114(9):1525-8. PubMed ID: 15475774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Decreasing oesophageal acid exposure in patients with GERD: a comparison of rabeprazole and omeprazole.
    Galmiche JP; Zerbib F; Ducrottè P; Fournet J; Rampal P; Avasthy N; Humphries TJ
    Aliment Pharmacol Ther; 2001 Sep; 15(9):1343-50. PubMed ID: 11552904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabeprazole for the prevention of pathologic and symptomatic relapse of erosive or ulcerative gastroesophageal reflux disease. Rebeprazole Study Group.
    Caos A; Moskovitz M; Dayal Y; Perdomo C; Niecestro R; Barth J
    Am J Gastroenterol; 2000 Nov; 95(11):3081-8. PubMed ID: 11095321
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of a single dose of rabeprazole 20 mg and pantoprazole 40 mg on 24-h intragastric acidity and oesophageal acid exposure: a randomized study in gastro-oesophageal reflux disease patients with a history of nocturnal heartburn.
    Miner P; Delemos B; Xiang J; Lococo J; Ieni J
    Aliment Pharmacol Ther; 2010 May; 31(9):991-1000. PubMed ID: 20132153
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review article: relief of symptoms in gastric acid-related diseases--correlation with acid suppression in rabeprazole treatment.
    Miner P
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 6():20-9. PubMed ID: 15496215
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized, double-blind, comparative study of standard-dose rabeprazole and high-dose omeprazole in gastro-oesophageal reflux disease.
    Holtmann G; Bytzer P; Metz M; Loeffler V; Blum AL
    Aliment Pharmacol Ther; 2002 Mar; 16(3):479-85. PubMed ID: 11876701
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn.
    DeVault KR
    Aliment Pharmacol Ther; 2006 Mar; 23 Suppl 1():33-9. PubMed ID: 16483268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of the reduction in gastric acidity necessary to prevent pathological oesophageal reflux in patients with gastro-oesophageal reflux disease treated with a proton pump inhibitor.
    Gardner JD; Sloan S; Miner PB; Robinson M
    Aliment Pharmacol Ther; 2003 Apr; 17(7):955-64. PubMed ID: 12656698
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.